Topic
13 stories from Planck Standard. Latest: July 13, 2026.
In preclinical experiments, the widely used medication telmisartan sharply boosted the tumor-killing power of the targeted drug olaparib and rallied the immune system to join the attack.
WashU scientists expected their mRNA vaccine to flop in mice missing the dendritic cells thought to be essential. Instead a related cell stepped in — overturning a core assumption and pointing toward sturdier shots.
Japanese researchers screening microbes from tree frogs, newts and lizards found one strain that erased colorectal tumors entirely — outperforming standard chemotherapy and immunotherapy in the lab.
Engineered nanoparticles triggered cancer cells to self-destruct while flipping 'cold' tumors 'hot,' producing complete remissions in mice when paired with immunotherapy.
UCLA researchers report that the popular muscle-building compound energizes dendritic cells — the immune system's scouts — potentially making cancer immunotherapy work for far more patients.
University of Washington scientists found that fibrolamellar carcinoma hides from immunotherapy by sequestering T cells in fibrous tissue — and that the FDA-approved drug AMD3100 lets them back in to kill the tumor.
Researchers identify NFIL3 as key factor causing engineered immune cells to lose cancer-fighting power, opening path to improved treatments.
Researchers found that disabling NFIL3 keeps engineered immune cells stronger for longer and improves tumor control in animal models.
Researchers identified NFIL3 as a major obstacle causing engineered immune cells to become exhausted and lose their cancer-fighting power, offering new hope for improving treatment of solid tumors.
Akeso and Summit Therapeutics report breakthrough results for ivonescimab in late-stage study, potentially offering new hope for patients with advanced lung cancer.
Pre-surgical pembrolizumab erased detectable disease in more than half of UCL-led trial patients, with no relapses after 33 months.
The pharmaceutical giant bets on revolutionary in vivo CAR-T technology that reprograms patients' immune cells inside the body. The deal represents Lilly's largest acquisition in years.
Zeaxanthin, a plant-based compound found in vegetables and eye-health supplements, strengthens T cells and enhances immunotherapy treatments in promising new research.